Kodiak Sciences Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of age-related macular degeneration, choroidal neovascularization, diabetic macular edema, dry eye, glaucoma, bacterial keratitis, retinitis and uveitis, among others.

Forward Therapeutics Inc. has disclosed TNF-α production inhibitors reported to be useful for the treatment of inflammation and autoimmune disorders.

Apellis Pharmaceuticals Inc. has identified C3 convertase inhibitors reported to be useful for the treatment of cancer, obesity, infections, neurological disorders, autoimmune and inflammatory disorders, age-related macular degeneration and chronic obstructive pulmonary disease (COPD), among others.

Recombination Therapeutics LLC and Thomas Jefferson University have synthesized DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.

Guangdong Newopp Biopharmaceuticals Co. Ltd. has identified macrocyclic derivatives acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Tibet Haisco Pharmaceutical Co. Ltd. has divulged myosin-2 (MYH2) inhibitors reported to be useful for the treatment of muscular dystrophy.

Haisco Pharmaceutical Group Co. Ltd. has discovered sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Blueprint Medicines Corp. has synthesized Cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.

Jiangsu Mingsheng Jutai Biotechnology Co. Ltd. has patented β-catenin (CTNNB1)/BCL9 interaction inhibitors reported to be useful for the treatment of cancer and fibrosis.

Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has discovered estrogen-related receptor α (ERRα; ERR1) inverse agonists reported to be useful for the treatment of cancer, obesity, hypertension, gallstone, osteoporosis, metabolic syndrome, hyperuricemia and Alzheimer's disease.